| 马 莹,王 晨.他扎罗汀与二丙酸倍他米松不同配比治疗寻常型银屑病疗效分析[J].中国烧伤创疡杂志,2023,(6):497~500. |
| DOI： |
| 中文关键词: 他扎罗汀 二丙酸倍他米松 配比 寻常型银屑病 生活质量 不良反应 |
| 英文关键词:Tazarotene Betamethasone dipropionate Ratio Psoriasis vulgaris Quality of life Adverse reaction |
| 基金项目: |
|
| 摘要点击次数: 1470 |
| 全文下载次数: 4178 |
| 中文摘要: |
| 【摘要】 目的 分析他扎罗汀与二丙酸倍他米松不同配比治疗寻常型银屑病的临床疗效。 方法 选取 2020年 1 月至 2022 年 1 月南阳市中心医院收治的 158 例寻常型银屑病患者作为研究对象, 按照随机数表法将其随机分为 A 组 (52 例)、 B 组 (52 例)、 C 组 (54 例), 采用他扎罗汀与二丙酸倍他米松浓度分别为 0.05% 与0.025% 、 0.02% 与 0.04% 、 0.05% 与 0.05% 的外用乳膏进行治疗, 对比观察 3 组患者皮损状态、 生活质量、 临床疗效及不良反应发生情况。 结果 治疗 1 个月后, C 组患者银屑病皮损面积和严重程度指数 (PASI) 评分及银屑病患者生活质量量表 (PQOLS) 评分均明显低于 A 组和 B 组 ( PASI 评分: q = 8.677、 9.864, P 均 < 0.001;PQOLS 评分: q = 10.923、 8.599, P 均 < 0.001), 但 A 组和 B 组间无明显差异 ( q = 1.176、 2.304, P = 0.684、0.236)。 治疗 1 个月后, C 组患者临床疗效明显优于 B 组 (Z = - 2.492, P = 0.013), 而 A 组和 B 组以及 A 组和C 组间无明显差异 (Z = - 0.918、 - 1.520, P = 0.359、 0.128); C 组患者治疗总有效率明显高于 A 组和 B 组(χ2= 4.604、 6.694, P = 0.032、 0.010), 而 A 组和 B 组间无明显差异 (χ2= 0.231, P = 0.631)。 治疗期间, 3 组患者不良反应发生率无明显差异 ( χ2= 0.785, P = 0.675)。 结论 他扎罗汀与二丙酸倍他米松的浓度配比为0.05% 与 0.05% 时治疗寻常型银屑病的疗效更好, 更能有效改善临床症状, 提高患者生活质量。 |
| 英文摘要: |
| 【Abstract】 Objective To analyze the clinical efficacy of tazarotene and betamethasone dipropionate at different ratios in the treatment of psoriasis vulgaris. Methods 158 patients with psoriasis vulgaris, admitted to Nanyang Central Hospital from January 2020 to January 2022, were enrolled as research subjects, and divided, using the random number table, into group A (n = 52), group B (n = 52) and group C (n = 54) to be treated with topical creams of tazarotene and betamethasone dipropionate at concentrations ratios of 0.05% and 0.025% , 0.02% and 0.04% , 0.05% and 0.05% , respectively. The skin lesions status, quality of life, clinical efficacy, and occurrence of adverse reactions in the three groups were compared. Results After one month of treatment, the scores of psoriasis area and severity index (PASI) and psoriasis quality of life scale (PQOLS) of patients in group C were both significantly lower than those in groups A and B (PASI score: q = 8.677 and 9.864, both P < 0.001; PQOLS score: q = 10.923 and 8.599, both P < 0.001), and therewas no significant difference between group A and group B in terms of the two scores (q = 1.176 and 2.304, P = 0.684 and 0.236). After one month of treatment, the clinical efficacy in group C was significantly better than that in group B (Z =- 2.492, P = 0.013), while there was no significant difference between group A and group B or between group A and group C ( Z = - 0.918 and - 1.520, P = 0.359 and 0.128 ). The total effective rate of treatment in group C was significantly higher than that in group A and group B (χ2 = 4.604 and 6.694, P = 0.032 and 0.010), while there was no significant difference between group A and group B ( χ2 = 0.231, P = 0.631). During the treatment period, there was no significant difference in the occurrence of adverse reactions among the three groups (χ 2= 0.785, P = 0.675). Conclusion Tazarotene and betamethasone dipropionate with their respective concentration ratio at 0.05% can realize better clinical efficacy in the treatment of psoriasis vulgaris, and effectively improve patients’ clinical symptoms and their quality of life. |
|
|
|
|
